Teva announces departure of President and CEO
30 October 2013 | By Teva Pharmaceutical Industries Ltd
Dr. Jeremy Levin will step down as President and Chief Executive Officer...
List view / Grid view
News
Abbott’s MitraClip® treatment demonstrates positive results for patients with degenerative mitral regurgitation at prohibitive risk for surgery
30 October 2013 | By Abbott
The MitraClip device provides physicians with a breakthrough treatment option for patients suffering from MR...
AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
Tecan’s AC Extraction Plate™ provides a unique sample preparation tool for LC-MS
29 October 2013 | By kdm communications
Tecan’s newly launched AC Extraction Plate is a revolutionary, automation-friendly solution designed to streamline sample preparation...
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
29 October 2013 | By GlaxoSmithKline
GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability...
Merck announces presentation of interim data from phase 1B study of MK-3475, investigational anti-PD-1 immunotherapy
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
Howie Mandel challenges people to learn the fibs and facts about atrial fibrillation and its associated increased stroke risk
28 October 2013 | By Bristol-Myers Squibb
“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
Promising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
New two-year results show SIMPONI® ARIA™ (GOLIMUMAB) for infusion inhibited radiographic progression in patients with active rheumatoid arthritis
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
Ethicon receives 510(K) clearance for new HARMONIC ACE®+ 7 SHEARS with advanced hemostasis
28 October 2013 | By Johnson & Johnson
Breakthrough technology in ultrasonic energy designed to improve surgeon confidence in vessel sealing...
Promising phase IIb data on Clazakizumab in patients with moderate-to-severe Rheumatoid Arthritis to be presented
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
Roche and Chugai’s investigational RoActemra® (tocilizumab) subcutaneous formulation shows comparable long-term efficacy and tolerability to the intravenous formulation in rheumatoid arthritis
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
